Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT04956302
What this trial is testing

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Abdullah Khan 1
Testing effectiveness (Phase 2)UnknownNCT04762745
What this trial is testing

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed, Refractory, Multiple Myeloma
Sun Yat-sen University 56
Not applicableUnknownNCT05066022
What this trial is testing

Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University 24
Very early researchLooking for participantsNCT06976437
What this trial is testing

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Who this might be right for
B Cell LymphomaMultiple Myeloma
YANRU WANG 21
Very early researchLooking for participantsNCT06730256
What this trial is testing

CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

Who this might be right for
Relapsed/Refractory Plasma Cell LeukemiaRelapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University 24
Testing effectiveness (Phase 2)WithdrawnNCT01492881
What this trial is testing

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00306813
What this trial is testing

Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
RelapseRefractory Multiple Myeloma
University of Wuerzburg 53
Early research (Phase 1)Looking for participantsNCT07280013
What this trial is testing

Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma (MM)
C4 Therapeutics, Inc. 60
Early research (Phase 1)Looking for participantsNCT05722418
What this trial is testing

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc. 50
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Early research (Phase 1)Ended earlyNCT02675452
What this trial is testing

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Acute Myeloid Leukemia
Amgen 141
Large-scale testing (Phase 3)Study completedNCT00111748
What this trial is testing

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

Who this might be right for
Multiple Myeloma
University of Arkansas 180
Not applicableStudy completedNCT00440635
What this trial is testing

Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen-Cilag International NV 641
Testing effectiveness (Phase 2)Ended earlyNCT05000450
What this trial is testing

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics 6
Early research (Phase 1)Ended earlyNCT00609817
What this trial is testing

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
La Jolla Pharmaceutical Company 9
Early research (Phase 1)Active Not RecruitingNCT06934044
What this trial is testing

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hoffmann-La Roche 20
Testing effectiveness (Phase 2)Ended earlyNCT03687125
What this trial is testing

Tinostamustine Conditioning and Autologous Stem Cell

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma ProgressionMultiple Myeloma With Failed Remission
Mundipharma-EDO GmbH 6
Large-scale testing (Phase 3)UnknownNCT03143049
What this trial is testing

Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Who this might be right for
Relapse Multiple Myeloma
National University Hospital, Singapore 120
Testing effectiveness (Phase 2)Ended earlyNCT04635735
What this trial is testing

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT01053949
What this trial is testing

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

Who this might be right for
Multiple Myeloma
University Hospital, Lille 84
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation